{"id":"denosumab-standard-dosing","safety":{"commonSideEffects":[{"rate":"5-13","effect":"Hypocalcemia"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-8","effect":"Nausea"},{"rate":"3-8","effect":"Dyspnea"},{"rate":"1-2","effect":"Osteonecrosis of the jaw"},{"rate":"<1","effect":"Atypical femoral fractures"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Denosumab targets receptor activator of nuclear factor kappa-B ligand (RANKL), a key mediator of osteoclast differentiation and survival. By blocking RANKL signaling, it reduces bone turnover and increases bone mineral density. This mechanism is used to prevent skeletal-related events in patients with bone metastases and to treat osteoporosis and hypercalcemia of malignancy.","oneSentence":"Denosumab is a monoclonal antibody that binds to RANKL, preventing bone resorption by inhibiting osteoclast formation and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:01.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of skeletal-related events in patients with bone metastases from solid tumors"},{"name":"Treatment of hypercalcemia of malignancy"},{"name":"Osteoporosis in postmenopausal women and men at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT02051218","phase":"PHASE3","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2014-07-16","conditions":"Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases","enrollment":1380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XGEVA®"],"phase":"phase_3","status":"active","brandName":"Denosumab (standard dosing)","genericName":"Denosumab (standard dosing)","companyName":"Swiss Cancer Institute","companyId":"swiss-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denosumab is a monoclonal antibody that binds to RANKL, preventing bone resorption by inhibiting osteoclast formation and activation. Used for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of hypercalcemia of malignancy, Osteoporosis in postmenopausal women and men at high risk of fracture.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}